Company / Cash & Equivalents
Edesa Biotech, Inc. Cash & Equivalents History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.2M
FY2021
5-year range
$4.6M / $7.9M
FY2017-FY2021
Trend
+43.4%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $7M over the past 3 years.
Based on SEC 10-K filings.
$7M in FY2021 with a 5-year CAGR of -1.7%.
Improved from $5M to $7M over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- -1.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.7%, indicating a declining trend.
- In FY2021, cash & equivalents increased 43.4% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $7.2M | +43.4% |
| FY2020 | $5.0M | +10.1% |
| FY2018 | $4.6M | -38.4% |
| FY2017 | $7.4M | -5.6% |
| FY2016 | $7.9M | +0.0% |
| FY2015 | $7.9M | +686.8% |
| FY2014 | $999.0K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026